Should I buy or sell Veru stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VERU shares. View VERU analyst ratings or view top-rated stocks .

What is Veru's stock price target for 2024?

3 brokerages have issued 1 year price objectives for Veru's shares. Their VERU share price targets range from $2.00 to $9.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 663.9% from the stock's current price. View analysts price targets for VERU or view top-rated stocks among Wall Street analysts .

How have VERU shares performed in 2023?

Veru's stock was trading at $5.28 on January 1st, 2023. Since then, VERU shares have decreased by 86.4% and is now trading at $0.72. View the best growth stocks for 2023 here .

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our VERU earnings forecast .

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Friday, December, 8th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The firm earned $3.86 million during the quarter, compared to the consensus estimate of $3.95 million. Veru had a negative trailing twelve-month return on equity of 374.04% and a negative net margin of 571.20%.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Corbus Pharmaceuticals (CRBP) , Matinas BioPharma (MTNB) , Organigram (OGI) , Vaxart (VXRT) , Rigel Pharmaceuticals (RIGL) , SCYNEXIS (SCYX) and VBI Vaccines (VBIV) .

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:VERU

Veru (VERU) Stock Price, News & Analysis

$0.72

-0.04 (-5.26%)

(As of 12/29/2023 ET)

Compare

Today's Range: $0.71
▼
$0.76
50-Day Range: $0.67
▼
$1.17
52-Week Range: $0.64
▼
$6.57

Volume: 1.54 million shs
Average Volume: 1.85 million shs
Market Capitalization: $67.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Veru MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 663.9% Upside
$5.50 Price Target
Short Interest: Bearish
13.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.57) to ($0.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

638th out of 950 stocks

Pharmaceutical Preparations Industry

309th out of 442 stocks

3.3

Analyst's Opinion

Consensus Rating
Veru has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Veru has a forecasted upside of 663.9% from its current price of $0.72.
Amount of Analyst Coverage
Veru has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.41% of the outstanding shares of Veru have been sold short.
Short Interest Ratio / Days to Cover
Veru has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Veru has recently decreased by 1.18%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Veru does not currently pay a dividend.
Dividend Growth
Veru does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERU.

3.8

News and Social Media Coverage

News Sentiment
Veru has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Veru this week, compared to 1 article on an average week.
Search Interest
14 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
4 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veru insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.90% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.12% of the stock of Veru is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Veru are expected to grow in the coming year, from ($0.57) to ($0.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veru is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veru is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veru has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Veru Stock (NASDAQ:VERU)

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VERU Stock News Headlines

December 19, 2023 | finance.yahoo.com

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

December 18, 2023 | finance.yahoo.com

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 29%

December 31, 2023 | Behind the Markets (Ad)

FINAL OFFER: $9 for a FULL YEAR of stock picks

We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?

December 14, 2023 | tmcnet.com

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

December 14, 2023 | msn.com

Veru stock falls after it prices its public offering at $0.72 per share

December 5, 2023 | nj.com

Mets address signing free agent who endured ‘bad luck’

November 23, 2023 | msn.com

Luton Town back Bedfordshire Police's knife crime campaign

November 11, 2023 | finance.yahoo.com

Veru Inc. (VERU) Stock Historical Prices & Data - Yahoo Finance

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

November 10, 2023 | finance.yahoo.com

The past year for Veru (NASDAQ:VERU) investors has not been profitable

October 16, 2023 | benzinga.com

VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU

October 13, 2023 | msn.com

Tandridge restaurant given new food hygiene rating

October 6, 2023 | ca.finance.yahoo.com

Veru Inc. (VERU)

October 5, 2023 | markets.businessinsider.com

Promising Drug Development Pipeline Bolsters Buy Rating for Veru: Enobosarm’s Potential and Upcoming Trials in Focus

October 4, 2023 | msn.com

Veru to conduct Phase2b study with enobosarm, GLP-1 weight-loss drugs

October 4, 2023 | finance.yahoo.com

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

September 27, 2023 | markets.businessinsider.com

Promising Drug Developments Bolster Veru’s Buy Rating: An Analysis of Sabizabulin and Enobosarm Trials

September 26, 2023 | finance.yahoo.com

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

September 20, 2023 | finance.yahoo.com

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

September 11, 2023 | finance.yahoo.com

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

August 30, 2023 | finance.yahoo.com

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

August 28, 2023 | msn.com

Veru: Stocks are being driven down by high valuations despite strong earnings

August 16, 2023 | finance.yahoo.com

Veru Inc. (NASDAQ:VERU) Analysts Just Trimmed Their Revenue Forecasts By 25%

August 14, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Veru (VERU)

August 11, 2023 | finance.yahoo.com

What You Can Learn From Veru Inc.'s (NASDAQ:VERU) P/S

August 10, 2023 | msn.com

Veru GAAP EPS of $0.07 beats by $0.27, revenue of $3.34M misses by $6.88M

August 10, 2023 | finance.yahoo.com

Veru Reports Fiscal 2023 Third Quarter Financial Results

See More Headlines

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/08/2023
Today: 12/31/2023
Next Earnings (Estimated): 2/08/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Sector: Medical
Current Symbol: NASDAQ:VERU
CUSIP: 31446210
CIK: 863894
Web: www.veruhealthcare.com
Phone: (305) 509-6897
Fax: 312-595-9122
Employees: 189
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $9.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +663.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,090,000.00
Net Margins: -571.20%
Pretax Margin: -568.26%
Return on Equity: -374.04%
Return on Assets: -136.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.16
Quick Ratio: 0.83

Sales & Book Value

Annual Sales: $16.30 million
Price / Sales: 4.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 3.60

Miscellaneous

Outstanding Shares: 93,670,000
Free Float: 73,159,000
Market Cap: $67.44 million
Optionable: Optionable
Beta: -0.12

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Mitchell S. Steiner F.A.C.S. (Age 62)
M.D., Chairman, President & CEO
Comp: $1.52M
Dr. Harry Fisch F.A.C.S. (Age 64)
M.D., Vice Chairman & Chief Corporate Officer
Comp: $708.81k
Dr. K. Gary Barnette Ph.D. (Age 55)
Chief Scientific Officer
Comp: $904.15k
Ms. Michele Greco (Age 64)
CFO & Chief Administrative Officer
Comp: $659.62k
Mr. Samuel Fisch
Executive Director of Investor Relations & Corporate Communications
Mr. Michael J. Purvis
Executive VP, General Counsel & Corporate Strategy and Secretary
Mr. Kevin J. Gilbert CPA
J.D., Executive Vice President of Corporate Development
Dr. Domingo Rodriguez M.D. (Age 61)
Executive Vice President of Global Clinical Operations
Dr. Gary Bird Ph.D.
Executive Vice President of Quality & Regulatory Affairs
Mr. Jason Davies
Executive VP and GM of UK, Europe, EMEA, LATAM & ASPAC

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VERU Stock Analysis - Frequently Asked Questions

Should I buy or sell Veru stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VERU shares.
View VERU analyst ratings or view top-rated stocks.
What is Veru's stock price target for 2024?: 3 brokerages have issued 1 year price objectives for Veru's shares. Their VERU share price targets range from $2.00 to $9.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 663.9% from the stock's current price.
View analysts price targets for VERU or view top-rated stocks among Wall Street analysts.
How have VERU shares performed in 2023?: Veru's stock was trading at $5.28 on January 1st, 2023. Since then, VERU shares have decreased by 86.4% and is now trading at $0.72.
View the best growth stocks for 2023 here.
When is Veru's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our VERU earnings forecast.

How were Veru's earnings last quarter?: Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Friday, December, 8th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The firm earned $3.86 million during the quarter, compared to the consensus estimate of $3.95 million. Veru had a negative trailing twelve-month return on equity of 374.04% and a negative net margin of 571.20%.
What other stocks do shareholders of Veru own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).
How do I buy shares of Veru?: Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERU) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial